Drug intelligence / Profile preview

SNS813

Development stage: Preclinical
Lead developer: Microbio

Overview

SNS813 is an investigational drug developed by Microbio (Shanghai) for the treatment of infectious diseases. It is currently in preclinical development. Specific details regarding its mechanism of action, molecular modality, or targeted indications have not been disclosed in public sources as of June 2025. There is no evidence that SNS813 has entered clinical trials or that it targets a specific pathogen or disease beyond the general category of infectious diseases[1].

Beyond the preview

Go deeper on SNS813.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNS813.

Explore the full profile